Antibiotic Resistance - Why is the Problem So Difficult to Solve?

Overview

Journal Infect Ecol Epidemiol

Specialty Microbiology

Date 2012 Sep 8

PMID 22957126

Citations 9

Authors

Soren Hojgard

Affiliations

Soon will be listed here.

Abstract

Antibiotic resistance has been increasing along with antibiotic use. At the same time, the supply of new drugs to replace those rendered inefficient by the development has been dwindling, leading to concerns that we may soon lack efficient means to treat bacterial infections. Though the problem has received considerable interest, there are no indications that the situation is about to change. The present review maintains that this is because the two objectives - preserving the efficiency of existing drugs and increasing the supply of new ones - are partly opposing. Hence, creating an incentive structure compatible with both of them is not easy. Nevertheless, it is suggested that levying a fee on the use of antibiotics, and earmarking the proceeds from this fee for subsidizing development of new antibiotics, would be an important step towards increasing incentives for a better antibiotic stewardship while preserving incentives to develop new substances.

Citing Articles

Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study.

Dutescu I, Hillier S Infect Drug Resist. 2021; 14:415-434.

PMID: 33574682 PMC: 7872909. DOI: 10.2147/IDR.S287792.

Reversal of carbapenem-resistance in by CRISPR/Cas9 genome editing.

Wu Z, Huang Y, Chao W, Ho S, Cheng J, Liu P J Adv Res. 2019; 18:61-69.

PMID: 30809393 PMC: 6374997. DOI: 10.1016/j.jare.2019.01.011.

Towards a global definition of responsible antibiotic use: results of an international multidisciplinary consensus procedure.

Monnier A, Eisenstein B, Hulscher M, Gyssens I J Antimicrob Chemother. 2018; 73(suppl_6):vi3-vi16.

PMID: 29878216 PMC: 5989615. DOI: 10.1093/jac/dky114.

Screening and Optimizing Antimicrobial Peptides by Using SPOT-Synthesis.

Lopez-Perez P, Grimsey E, Bourne L, Mikut R, Hilpert K Front Chem. 2017; 5:25.

PMID: 28447030 PMC: 5388751. DOI: 10.3389/fchem.2017.00025.

Bloodstream infections in intensive care unit patients: distribution and antibiotic resistance of bacteria.

Russotto V, Cortegiani A, Graziano G, Saporito L, Raineri S, Mammina C Infect Drug Resist. 2015; 8:287-96.

PMID: 26300651 PMC: 4536838. DOI: 10.2147/IDR.S48810.

References

ASHLEY D, Brindle M . Penicillin resistance in staphylococci isolated in a casualty department. J Clin Pathol. 1960; 13:336-8. PMC: 480091. DOI: 10.1136/jcp.13.4.336. View

Vernon J, Golec J, DiMasi J . Drug development costs when financial risk is measured using the Fama-French three-factor model. Health Econ. 2009; 19(8):1002-5. DOI: 10.1002/hec.1538. View

Siegel J, Rhinehart E, Jackson M, Chiarello L . Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control. 2007; 35(10 Suppl 2):S165-93. DOI: 10.1016/j.ajic.2007.10.006. View

Murray B . Can antibiotic resistance be controlled?. N Engl J Med. 1994; 330(17):1229-30. DOI: 10.1056/NEJM199404283301710. View

Shlaes D . The abandonment of antibacterials: why and wherefore?. Curr Opin Pharmacol. 2003; 3(5):470-3. DOI: 10.1016/j.coph.2003.04.003. View

Clatworthy A, Pierson E, Hung D . Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol. 2007; 3(9):541-8. DOI: 10.1038/nchembio.2007.24. View

Horowitz J, Moehring H . How property rights and patents affect antibiotic resistance. Health Econ. 2004; 13(6):575-83. DOI: 10.1002/hec.851. View

Goldmann D, Weinstein R, Wenzel R, Tablan O, DUMA R, Gaynes R . Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership. JAMA. 1996; 275(3):234-40. View

Adams C, Brantner V . Estimating the cost of new drug development: is it really 802 million dollars?. Health Aff (Millwood). 2006; 25(2):420-8. DOI: 10.1377/hlthaff.25.2.420. View

10.

DiMasi J, Hansen R, Grabowski H . The price of innovation: new estimates of drug development costs. J Health Econ. 2003; 22(2):151-85. DOI: 10.1016/S0167-6296(02)00126-1. View

11.

Tillotson G . Stimulating antibiotic development. Lancet Infect Dis. 2010; 10(1):2-3. DOI: 10.1016/S1473-3099(09)70333-0. View

12.

Coast J, Smith R, Millar M . Superbugs: should antimicrobial resistance be included as a cost in economic evaluation?. Health Econ. 1996; 5(3):217-26. DOI: 10.1002/(SICI)1099-1050(199605)5:3<217::AID-HEC200>3.0.CO;2-S. View

13.

Projan S . Why is big Pharma getting out of antibacterial drug discovery?. Curr Opin Microbiol. 2003; 6(5):427-30. DOI: 10.1016/j.mib.2003.08.003. View

14.

Levy J . Antibiotic resistance in Europe and the current use of antibiotics in severe pediatric infections. Scand J Infect Dis Suppl. 1990; 73:23-9. View

15.

POWERS J . Antimicrobial drug development--the past, the present, and the future. Clin Microbiol Infect. 2004; 10 Suppl 4:23-31. DOI: 10.1111/j.1465-0691.2004.1007.x. View

16.

Allerberger F, Gareis R, Jindrak V, Struelens M . Antibiotic stewardship implementation in the EU: the way forward. Expert Rev Anti Infect Ther. 2009; 7(10):1175-83. DOI: 10.1586/eri.09.96. View

17.

Noskin G, Rubin R, Schentag J, Kluytmans J, Hedblom E, Smulders M . The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med. 2005; 165(15):1756-61. DOI: 10.1001/archinte.165.15.1756. View

18.

Projan S, Shlaes D . Antibacterial drug discovery: is it all downhill from here?. Clin Microbiol Infect. 2004; 10 Suppl 4:18-22. DOI: 10.1111/j.1465-0691.2004.1006.x. View

19.

Dellit T, Owens R, McGowan Jr J, Gerding D, Weinstein R, Burke J . Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2006; 44(2):159-77. DOI: 10.1086/510393. View

20.

Elbasha E . Deadweight loss of bacterial resistance due to overtreatment. Health Econ. 2003; 12(2):125-38. DOI: 10.1002/hec.702. View